Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
SPOTLIGHT: Merck posts $1.6 billion loss
Merck reported a whopping $1.6 billion loss for the fourth quarter, mostly because of massive accounting charges related to its $4.85 billion Vioxx settlement. During the same period last year, Merck posted a $473.9 million profit. Meanwhile, some Florida patients left out of the Vioxx deal now want in. Report | Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
